A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether patients with liver cirrhosis have acceptable outcomes after undergoing cardiac surgery. Altogether 97 papers were found using the reported search, of which nine presented the best evidence to answer the clinical question. The author, year, journal, country of study, study type, patient group studied, relevant outcomes, results and study weaknesses were tabulated. One prospective and another eight retrospective studies involving adult population of patients with liver cirrhosis undergoing various cardiac surgical procedures were selected. In these studies, the overall mortality was 17.1% and combined mean mortality for Child-Pugh class A, B and C was 5.2%, 35.4% and 70%, respectively. The major morbidity ranged from 20 to 60% in group A and 50 to 100% in the patients with more advanced hepatic disease. Some studies have demonstrated that thrombocytopenia, decreased serum cholinesterase and high preoperative total bilirubin levels are significantly associated with worse clinical outcomes. These studies, although with small samples, collectively demonstrate that patients with Child-Pugh class A cirrhosis tolerated cardiac surgical procedures with a mild increase in mortality and morbidity. However, the risk of mortality in patients with Child-Pugh class B and C or MELD score )13 is extremely high. Nevertheless, even if these patients underwent successful surgery, their long-term survival was significantly poorer and their health status remains compromised even well after cardiac surgery because of persistent liver dysfunction.
Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in ICVTS w1x.
Clinical scenario
A 66-year-old man with alcohol-related liver cirrhosis presents with dyspnoea (NYHA II). Echocardiogram demonstrated severe mitral regurgitation due to posterior mitral leaflet prolapse, good left ventricular systolic function and increased pulmonary artery pressures. Coronary angiogram is pending your decision-making in favour of surgery. You routinely use EuroSCORE to risk stratify but this does not account for liver cirrhosis. Therefore, you resolve to search the literature to find the best evidence.
Three-part question
Do wpatients with liver cirrhosisx, undergoing wcardiac surgeryx have acceptable wclinical outcomesx? 
Search strategy
Medline 1950 to March 2010 using the OVID interface. wexp Thoracic SurgeryyOR heart surgery.mp. OR valve surgery.mp. OR exp Coronary Artery BypassyOR cardiac surgery.mp.x AND wliver dysfunction.mp. or exp Liver DiseasesyOR Cirrhosis.mp.x
Search outcome
Four hundred and forty papers were found, of which nine were included in the BET analysis reported below. The relevant papers are presented in Table 1 .
Comments
Nine clinical studies, one prospective and eight retrospective, involving 210 adult patients were found to be suitable. The studies looked at the clinical outcomes of patients with liver cirrhosis undergoing a wide range of cardiac surgical procedures.
An et al. w2x studied 24 patients with liver cirrhosis who underwent cardiac surgery to evaluate morbidity, mortality and predictors of outcome. Patients were divided into three groups based on Child-Pugh classification (CPC). They observed that 53% patients with class A cirrhosis and 100% with class B and C cirrhosis suffered postoperative compli-A. Modi et al. / Interactive CardioVascular and Thoracic Surgery 11 (2010) cations. Postoperative mortality of patients with class A, class B and class C cirrhosis were 6%, 67%, and 100%, respectively. Increased total serum bilirubin levels, low serum cholinesterase levels preoperatively and prolonged cardiopulmonary bypass (CPB) times were found to be predictors of worse outcome. Murashita et al. w3x reviewed clinical outcomes and aimed to determine risk factors for mortality for 12 cirrhotic patients who underwent cardiac surgery. Six patients each, with class A and B cirrhosis had a mortality of 50% and 17%, and morbidity of 50% and 100%, respectively. Patients who experienced major morbidities had markedly lower levels of serum cholinesterase (Ps0.02) and lower platelet level (Ps0.04). An excellent retrospective review by Filsoufi and colleagues w4x including Best Evidence Topic 27 patients with cirrhosis who underwent cardiac surgery demonstrated that stratified mortality according to CPC was 11%, 18%, and 67% for class A, B, and C, respectively. No mortality occurred in patients who had 'off' pump revascularisation (ns5). Major postoperative complications occurred in 22%, 56%, and 100% for CPC class A, B, and C, respectively. One-year survival was 80%, 45%, and 16%, respectively (Ps0.02) and the long-term survival was significantly lower in cirrhotic patients compared to overall patient population (Ps0.001). Further, they deduced that CPC was a better predictor of hospital mortality (Ps0.02) compared to model for end-stage liver disease (MELD) score (Ps0.065). Morisaki et al. w5x reviewed 42 cirrhotic patients who underwent cardiovascular operations (CPC A, ns30; CPC B, ns12). They reported 33% mortality in class B with 31% (ns13) overall morbidity. Lower platelet counts and higher MELD scores were preoperative risk factors and operation time, CPB time and aortic cross-clamp time were intraoperative risk factors for hospital morbidity. A higher incidence of hospital morbidity was predicted by platelet counts of -96,000yml or MELD scores )13. Suman et al. w6x, conducted a retrospective study to quantify the risk of cardiac surgery in patients with cirrhosis and reported that the association of hepatic decompensation and mortality with Child-Pugh class, Child-Pugh score, and MELD score was significant (P-0.005). Twenty-seven percent developed hepatic decompensation and 16% patients died. A 'cut-off' Child-Pugh score )7 was found to have a sensitivity and specificity of 86% and 92% for mortality, with a negative predictive value of 97% and positive predictive value of 67%, respectively. A series of 18 patients with cirrhosis undergoing cardiac procedures was analysed by Lin et al. w7x , and found an overall in-hospital mortality rate of 6% with a major morbidity rate of 39% in CPC A and 80% in CPC B and C. Thirteen similar patients were retrospectively reviewed by Klemperer and colleagues w8x. With eight patients in CPC A and five in CPC B, they observed major postoperative complications in 25% and 100%, respectively. There was no mortality in CPC A but 80% of patients in CPC B died. They concluded that patients with minimal clinical evidence of cirrhosis can tolerate CPB and cardiac surgical procedures, whereas those with more advanced liver disease should not be offered operation. Hayashida et al. w9x assessed perioperative mortality and major organ morbidity in 18 cardiac surgical cirrhotic patients. They observed that the hospital mortality of patients with class A, class B, and class C cirrhosis undergoing CPB was 0%, 50%, and 100%. No deaths were observed in 'off' pump patients belonging to CPC B. Similarly, major complications were observed in 60% of those with class A cirrhosis and 100% of those with class B cirrhosis and class C cirrhosis undergoing CPB but only 33% of the class B patients without CPB. They concluded saying that 'off' pump surgery can be an alternative therapeutic strategy for patients with advanced cirrhosis requiring surgical revascularisation. Bizouarn et al. w10x performed a prospective study to evaluate the early and late outcome after elective cardiac surgery in patients with cirrhosis with 10 patients in CPC A and two in CPC B. No mortality was observed in CPC A and 50% in CPC B. However, the complications remained as high as 50% and 100% in the two groups, respectively. They inferred that the incidence of significant complications was high even after elective cardiac surgery and the health status remained compromised even well after the operation because of persistent liver dysfunction.
Clinical bottom line
These studies demonstrate that cardiac surgery could be offered to patients with Child-Pugh A and a low MELD score with mild increase in the risk of mortality (Table 2) . However, for patients with more advanced cirrhosis, the risk of mortality is unacceptably high. Revascularisation without the use of CPB may be lower risk but in these patients long-term survival is significantly poor and health status is compromised even well after cardiac surgery.
